Following receipt of regulatory and other necessary approvals and completion of the flagship facility, Etain will have access to a state-of-the-art cannabis cultivation and manufacturing facility that RIV Capital and Etain believe will increase the diversity, breadth, and volume of Etain's product offerings, improve affordability and access for New York patients and consumers, and provide a platform to bring successful, authentic cannabis brands to New York.
Photo: Benzinga; Sources: courtesy of Matthias Zomer via Pexels, squarefrog via Pixabay
Related News
Riv Capital Cuts FY 22 Net Loss By 61%, Expects Completion Of Etain Acquisition In H2 22
Riv Capital Is Being Sued By JW Asset Management, Here Are The Details
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
